|
|
 Previous Article | Table of Contents | Next Article 
Constitutive expression of Mpl ligand transcripts during thrombocytopenia
or thrombocytosis
K Cohen-Solal, JL Villeval, M Titeux, S Lok, W Vainchenker and F Wendling
INSERM U 362, Institut Gustave Roussy, Villejuif, France.
Mpl ligand (thrombopoietin [TPO]) is the physiological regulator of
platelet production. In mice, mRNA encoding the Mpl ligand (Mpl-L) is
predominantly found by Northern blot analysis in the liver and kidney. To
investigate the mode of regulation of the Mpl-L gene, we have developed
several experimental models of severe thrombocytopenia differing in their
kinetics and an opposite model of chronic thrombocytosis. Northern analysis
performed at various times after induction of a thrombocytopenic state
demonstrates that, whatever the number of circulating platelets, no change
in Mpl-L mRNA level occurs in liver and kidney. By ribonuclease protection
assays, we analyzed the ratios between mRNAs coding for the wild-type Mpl-L
form and various splice variants encoding inactive or nonsecreted Mpl-L
proteins. No modification in levels of these various isoforms was detected
confirming the data of a previous report. Because the highest level of
Mpl-L bioactivity in sera was observed only in mice with drastically
reduced numbers of both platelets and megakaryocytes, these results further
suggest that not only platelets, but also megakaryocytes, must be involved
in the regulation of the level of circulating Mpl-L. In addition, we show
that no downregulation of wild-type Mpl-L mRNA and no change in the ratio
of Mpl-L mRNA isoforms were detected in mice in which a chronic
thrombocytosis was induced. Together, these different models extend and
further confirm that the regulation of Mpl-L does not occur at a
transcriptional level or by a modulation in the ratios of Mpl-L mRNA
isoforms.
Volume 88,
Issue 7,
pp. 2578-2584,
10/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. P. Lambert, L. Rauova, M. Bailey, M. C. Sola-Visner, M. A. Kowalska, and M. Poncz
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications
Blood,
August 15, 2007;
110(4):
1153 - 1160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock
Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited
Clin. Cancer Res.,
February 15, 2005;
11(4):
1361 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli
Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2002;
8(3):
193 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Ando, Y. Iwamoto, A. Suda, K. Tsuchiya, and H. Nihei
New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels
Blood,
February 15, 2001;
97(4):
915 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Solanilla, J. Dechanet, A. El Andaloussi, M. Dupouy, F. Godard, J. Chabrol, P. Charbord, J. Reiffers, A. T. Nurden, B. Weksler, et al.
CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells
Blood,
June 15, 2000;
95(12):
3758 - 3764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cazzola and R. C. Skoda
Translational pathophysiology: a novel molecular mechanism of human disease
Blood,
June 1, 2000;
95(11):
3280 - 3288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Barosi
Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines
J. Clin. Oncol.,
September 1, 1999;
17(9):
2954 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Altun, M. Arici, I. C. Haznedaroglu, C. Usalan, Y. Erdem, U. Yasavul, C. Turgan, S. Caglar, and S. Kirazli
Serum thrombopoietin levels in haemodialysis patients: involvement of arteriovenous fistula
Nephrol. Dial. Transplant.,
September 1, 1999;
14(9):
2173 - 2177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.-M. Wolber, C. Dame, H. Fahnenstich, D. Hofmann, P. Bartmann, W. Jelkmann, and J. Fandrey
Expression of the Thrombopoietin Gene in Human Fetal and Neonatal Tissues
Blood,
July 1, 1999;
94(1):
97 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Cohen-Solal, N. Vitrat, M. Titeux, W. Vainchenker, and F. Wendling
High-Level Expression of Mpl in Platelets and Megakaryocytes Is Independent of Thrombopoietin
Blood,
May 1, 1999;
93(9):
2859 - 2866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chang, J. X. Qian, S. m. Lee, J. Joubran, G. Fernandez, J. Nichols, A. Knoppel, and J. S. Buzby
Tissue Uptake of Circulating Thrombopoietin Is Increased in Immune-Mediated Compared With Irradiated Thrombocytopenic Mice
Blood,
April 15, 1999;
93(8):
2515 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Taksin, J.-P. L. Couedic, I. Dusanter-Fourt, A. Masse, S. Giraudier, A. Katz, F. Wendling, W. Vainchenker, N. Casadevall, and N. Debili
Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L
Blood,
January 1, 1999;
93(1):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ghilardi, A. Wiestner, and R. C. Skoda
Thrombopoietin Production Is Inhibited by a Translational Mechanism
Blood,
December 1, 1998;
92(11):
4023 - 4030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kondo, M. Okabe, M. Sanada, M. Kurosawa, S. Suzuki, M. Kobayashi, M. Hosokawa, and M. Asaka
Familial Essential Thrombocythemia Associated With One-Base Deletion in the 5'-Untranslated Region of the Thrombopoietin Gene
Blood,
August 15, 1998;
92(4):
1091 - 1096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Villeval, K. Cohen-Solal, M. Tulliez, S. Giraudier, J. Guichard, S. A. Burstein, E. M. Cramer, W. Vainchenker, and F. Wendling
High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice
Blood,
December 1, 1997;
90(11):
4369 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Shivdasani, P. Fielder, G.-A. Keller, S. H. Orkin, and F. J. de Sauvage
Regulation of the Serum Concentration of Thrombopoietin in Thrombocytopenic NF-E2 Knockout Mice
Blood,
September 1, 1997;
90(5):
1821 - 1827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Goncalves, C. Lacout, J.-L. Villeval, F. Wendling, W. Vainchenker, and D. Dumenil
Thrombopoietin Does Not Induce Lineage-Restricted Commitment of Mpl-R Expressing Pluripotent Progenitors But Permits Their Complete Erythroid and Megakaryocytic Differentiation
Blood,
May 15, 1997;
89(10):
3544 - 3553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
